Net Profit Margin
since 2005
Calculation
Bristol-Myers Squibb Co., net profit margin, long-term trends, calculation
| Net profit margin | = | 100 | × | Net earnings (loss) attributable to BMS1 | ÷ | Revenues1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 14.64% | = | 100 | × | 7,054) | ÷ | 48,194) |
| Dec 31, 2024 | -18.53% | = | 100 | × | (8,948) | ÷ | 48,300) |
| Dec 31, 2023 | 17.83% | = | 100 | × | 8,025) | ÷ | 45,006) |
| Dec 31, 2022 | 13.71% | = | 100 | × | 6,327) | ÷ | 46,159) |
| Dec 31, 2021 | 15.08% | = | 100 | × | 6,994) | ÷ | 46,385) |
| Dec 31, 2020 | -21.20% | = | 100 | × | (9,015) | ÷ | 42,518) |
| Dec 31, 2019 | 13.15% | = | 100 | × | 3,439) | ÷ | 26,145) |
| Dec 31, 2018 | 21.81% | = | 100 | × | 4,920) | ÷ | 22,561) |
| Dec 31, 2017 | 4.85% | = | 100 | × | 1,007) | ÷ | 20,776) |
| Dec 31, 2016 | 22.94% | = | 100 | × | 4,457) | ÷ | 19,427) |
| Dec 31, 2015 | 9.45% | = | 100 | × | 1,565) | ÷ | 16,560) |
| Dec 31, 2014 | 12.62% | = | 100 | × | 2,004) | ÷ | 15,879) |
| Dec 31, 2013 | 15.64% | = | 100 | × | 2,563) | ÷ | 16,385) |
| Dec 31, 2012 | 11.12% | = | 100 | × | 1,960) | ÷ | 17,621) |
| Dec 31, 2011 | 17.46% | = | 100 | × | 3,709) | ÷ | 21,244) |
| Dec 31, 2010 | 15.92% | = | 100 | × | 3,102) | ÷ | 19,484) |
| Dec 31, 2009 | 56.42% | = | 100 | × | 10,612) | ÷ | 18,808) |
| Dec 31, 2008 | 25.47% | = | 100 | × | 5,247) | ÷ | 20,597) |
| Dec 31, 2007 | 11.19% | = | 100 | × | 2,165) | ÷ | 19,348) |
| Dec 31, 2006 | 8.85% | = | 100 | × | 1,585) | ÷ | 17,914) |
| Dec 31, 2005 | 15.62% | = | 100 | × | 3,000) | ÷ | 19,207) |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in millions
The net profit margin exhibited considerable fluctuation over the period from 2005 to 2025. Initial values demonstrated a strong profitability, followed by periods of volatility and significant shifts in performance. A detailed examination reveals distinct phases in the company’s profitability trends.
- Initial Period (2005-2009)
- From 2005 to 2006, the net profit margin decreased substantially from 15.62% to 8.85%. It then recovered to 11.19% in 2007 before experiencing a dramatic increase to 25.47% in 2008. This was followed by a peak of 56.42% in 2009, representing the highest margin observed throughout the analyzed timeframe. This period suggests a potential for significant earnings improvement, though the volatility is notable.
- Moderate Fluctuations (2010-2014)
- The net profit margin declined to 15.92% in 2010, followed by a slight increase to 17.46% in 2011. A decrease was then observed in 2012, falling to 11.12%. The margin recovered somewhat in 2013 and 2014, reaching 15.64% and 12.62% respectively. This phase indicates a period of relative stability, albeit with fluctuations, in profitability.
- Continued Volatility (2015-2019)
- The net profit margin experienced a substantial increase to 22.94% in 2015, followed by a sharp decline to 4.85% in 2017. A recovery occurred in 2018, rising to 21.81%, and continued into 2019 with a margin of 13.15%. This period demonstrates a high degree of sensitivity to underlying business conditions.
- Significant Shifts (2020-2025)
- In 2020, the net profit margin turned negative, reaching -21.20%, a substantial downturn. A recovery was seen in 2021 (15.08%) and 2022 (13.71%), with a further increase to 17.83% in 2023. However, 2024 witnessed another significant negative margin of -18.53%, followed by a partial recovery to 14.64% in 2025. This recent period is characterized by substantial swings in profitability, indicating potential challenges or significant restructuring events impacting earnings.
Overall, the net profit margin demonstrates a pattern of considerable variability. While periods of strong profitability were observed, particularly in 2009 and 2015, the company also experienced significant losses in 2020 and 2024. The fluctuations suggest the company’s earnings are susceptible to external factors or internal strategic shifts. The recent trend indicates a potential for ongoing instability in profitability.
Comparison to Competitors
Bristol-Myers Squibb Co., net profit margin, long-term trends, comparison to competitors
| Bristol-Myers Squibb Co. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 14.64% | 6.91% | 21.94% | 14.71% | 31.67% | 29.43% | 28.46% | 28.08% | 12.42% | 31.41% | 15.05% | 32.94% |
| Dec 31, 2024 | -18.53% | 7.59% | 12.77% | 16.33% | 23.51% | 1.68% | 15.84% | 26.68% | 12.62% | 31.07% | 14.77% | -4.86% |
| Dec 31, 2023 | 17.83% | 8.95% | 24.96% | 19.94% | 15.36% | 21.03% | 41.28% | 0.61% | 3.56% | 30.14% | 13.99% | 36.68% |
| Dec 31, 2022 | 13.71% | 20.39% | 26.42% | 22.91% | 21.88% | 17.02% | 18.90% | 24.49% | 31.01% | 35.64% | 15.47% | 37.20% |
| Dec 31, 2021 | 15.08% | 20.54% | 24.25% | 21.84% | 19.71% | 23.05% | 22.26% | 26.79% | 26.76% | 50.25% | 19.70% | 30.92% |
| Dec 31, 2020 | -21.20% | 10.08% | 29.97% | 16.36% | 25.24% | 0.51% | 17.82% | 14.72% | 22.53% | 41.35% | 19.79% | 43.70% |
| Dec 31, 2019 | 13.15% | 23.69% | 35.32% | 16.80% | 37.27% | 24.35% | 18.42% | 21.01% | 31.45% | 26.91% | 14.47% | 28.27% |
| Dec 31, 2018 | 21.81% | 17.36% | 37.25% | 13.33% | 13.16% | 25.16% | 18.75% | 14.71% | 20.79% | 36.42% | 12.06% | 68.80% |
| Dec 31, 2017 | 4.85% | 18.82% | 9.08% | 13.60% | -0.89% | 18.03% | 1.70% | 5.97% | 40.55% | 20.41% | 10.64% | 10.59% |
| Dec 31, 2016 | 22.94% | 23.22% | 35.27% | 15.13% | 12.90% | 45.07% | 23.01% | 9.85% | 13.66% | 18.42% | 11.06% | -6.58% |
| Dec 31, 2015 | 9.45% | 22.50% | 33.13% | 16.33% | 12.07% | 56.32% | 21.99% | 11.25% | 14.25% | 15.50% | 11.64% | -53.89% |
| Dec 31, 2014 | 12.62% | 8.89% | 26.69% | 13.05% | 12.19% | 49.44% | 21.96% | 28.22% | 18.42% | 12.34% | 11.22% | -127.25% |
| Dec 31, 2013 | 15.64% | 21.97% | 27.93% | 14.10% | 20.27% | 28.46% | 19.40% | 10.00% | 42.65% | 20.16% | 9.73% | -36.72% |
| Dec 31, 2012 | 11.12% | 28.70% | 26.11% | 13.10% | 18.09% | 27.57% | 16.14% | 13.05% | 24.70% | 54.43% | 9.42% | -7.01% |
| Dec 31, 2011 | 17.46% | — | 24.08% | 13.50% | 17.90% | 34.60% | 14.87% | 13.05% | 14.84% | -49.74% | 11.34% | 2.10% |
| Dec 31, 2010 | 15.92% | — | 31.56% | 13.58% | 21.97% | 39.26% | 21.65% | 1.87% | 12.18% | -22.76% | 9.60% | -526.35% |
| Dec 31, 2009 | 56.42% | — | 32.09% | 10.30% | 19.82% | 40.74% | 19.82% | 47.04% | 17.27% | -17.88% | 8.41% | -630.27% |
| Dec 31, 2008 | 25.47% | — | 28.57% | 10.38% | -10.17% | 39.55% | 20.31% | 32.74% | 16.78% | -34.69% | 9.47% | -262.02% |
| Dec 31, 2007 | 11.19% | — | 22.12% | 12.42% | 15.85% | 43.27% | 17.31% | 13.54% | 16.82% | -84.46% | 7.81% | -196.61% |
| Dec 31, 2006 | 8.85% | — | 21.29% | 11.69% | 16.97% | -45.98% | 20.73% | 19.59% | 39.98% | -161.30% | 4.46% | -95.63% |
| Dec 31, 2005 | 15.62% | — | 30.56% | 11.24% | 13.52% | 44.99% | 20.61% | 21.04% | 15.76% | -144.19% | 8.48% | -126.43% |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Bristol-Myers Squibb Co., net profit margin, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Bristol-Myers Squibb Co. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2025 | 14.64% | 21.54% |
| Dec 31, 2024 | -18.53% | 12.30% |
| Dec 31, 2023 | 17.83% | 17.95% |
| Dec 31, 2022 | 13.71% | 22.55% |
| Dec 31, 2021 | 15.08% | 23.38% |
| Dec 31, 2020 | -21.20% | 14.07% |
| Dec 31, 2019 | 13.15% | 23.22% |
| Dec 31, 2018 | 21.81% | 19.82% |
| Dec 31, 2017 | 4.85% | 13.06% |
| Dec 31, 2016 | 22.94% | 20.78% |
| Dec 31, 2015 | 9.45% | 21.17% |
| Dec 31, 2014 | 12.62% | 21.24% |
| Dec 31, 2013 | 15.64% | 21.99% |
| Dec 31, 2012 | 11.12% | 18.53% |
| Dec 31, 2011 | 17.46% | 15.70% |
| Dec 31, 2010 | 15.92% | 15.16% |
| Dec 31, 2009 | 56.42% | 25.73% |
| Dec 31, 2008 | 25.47% | 18.17% |
| Dec 31, 2007 | 11.19% | 15.90% |
| Dec 31, 2006 | 8.85% | 22.24% |
| Dec 31, 2005 | 15.62% | 18.33% |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Bristol-Myers Squibb Co., net profit margin, long-term trends, comparison to industry (health care)
| Bristol-Myers Squibb Co. | Health Care | |
|---|---|---|
| Dec 31, 2025 | 14.64% | 11.79% |
| Dec 31, 2024 | -18.53% | 8.84% |
| Dec 31, 2023 | 17.83% | 11.49% |
| Dec 31, 2022 | 13.71% | 14.65% |
| Dec 31, 2021 | 15.08% | 15.24% |
| Dec 31, 2020 | -21.20% | 10.27% |
| Dec 31, 2019 | 13.15% | 14.56% |
| Dec 31, 2018 | 21.81% | 12.61% |
| Dec 31, 2017 | 4.85% | 9.26% |
| Dec 31, 2016 | 22.94% | 12.80% |
| Dec 31, 2015 | 9.45% | 13.94% |
| Dec 31, 2014 | 12.62% | 14.40% |
| Dec 31, 2013 | 15.64% | 15.04% |
| Dec 31, 2012 | 11.12% | 13.92% |
| Dec 31, 2011 | 17.46% | 12.06% |
| Dec 31, 2010 | 15.92% | 11.90% |
| Dec 31, 2009 | 56.42% | 17.77% |
| Dec 31, 2008 | 25.47% | 13.00% |
| Dec 31, 2007 | 11.19% | 12.52% |
| Dec 31, 2006 | 8.85% | 15.30% |
| Dec 31, 2005 | 15.62% | 14.61% |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).